The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia
Katherine A. Minson(Children's Healthcare of Atlanta), Douglas K. Graham(Emory University)
Cited by 78
Related Papers
Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia
|Oncogene|2013|105
Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia
|Blood Cancer Journal|2013|57